PRCT 📈 Procept Biorobotics - Overview
Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US74276L1052
PRCT: Surgical Robotic Systems, Urology Treatment Devices
Procept Biorobotics Corp, listed on the NASDAQ under the ticker PRCT, is a pioneering company in the field of surgical robotics, specifically targeting the urology sector. By developing and commercializing innovative solutions, the company aims to transform the landscape of urologic surgery, both in the United States and globally. One of its flagship products is the AquaBeam Robotic System, a cutting-edge, image-guided robotic platform designed for minimally invasive procedures. This system is particularly focused on treating benign prostatic hyperplasia (BPH), a common condition affecting men that can lead to lower urinary tract symptoms.
The AquaBeam Robotic System is complemented by Aquablation therapy, a procedure designed to provide relief to males suffering from the symptoms of BPH. This therapy represents a significant advancement in the treatment of BPH, offering a minimally invasive alternative to traditional surgical methods. By leveraging robotic technology and advanced imaging, Procept Biorobotics Corp is poised to make a significant impact on the standard of care for BPH patients, potentially improving outcomes and reducing recovery times. The company's commitment to innovation and patient care is reflected in its continuous development and refinement of these technologies.
Founded in 2007 and headquartered in San Jose, California, Procept Biorobotics Corp has established itself as a key player in the health care equipment sector, specifically within the sub-industry of health care equipment. With its common stock listed under the ISIN US74276L1052, the company is accessible to investors looking to be part of the evolving landscape of medical technology. For more information on Procept Biorobotics Corp and its groundbreaking work in surgical robotics and urologic care, one can visit the company's website at https://www.procept-biorobotics.com. The company's classification under the GICS Sub Industry of Health Care Equipment underscores its role in developing and manufacturing critical equipment for medical procedures.
Additional Sources for PRCT Stock
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
PRCT Stock Overview
Market Cap in USD | 4,838m |
Sector | Healthcare |
Industry | Medical Devices |
GiC Sub-Industry | Health Care Equipment |
IPO / Inception | 2021-09-15 |
PRCT Stock Ratings
Growth 5y | 68.0% |
Fundamental | -29.1% |
Dividend | - |
Rel. Strength Industry | 3856 |
Analysts | 4.4/5 |
Fair Price Momentum | 89.28 USD |
Fair Price DCF | - |
PRCT Dividends
No Dividends PaidPRCT Growth Ratios
Growth Correlation 3m | 56.1% |
Growth Correlation 12m | 93.3% |
Growth Correlation 5y | 62% |
CAGR 5y | 22.31% |
CAGR/Mean DD 5y | 1.06 |
Sharpe Ratio 12m | 1.26 |
Alpha | 54.35 |
Beta | 1.59 |
Volatility | 70.81% |
Current Volume | 1288k |
Average Volume 20d | 592.2k |
As of December 21, 2024, the stock is trading at USD 81.17 with a total of 1,288,040 shares traded.
Over the past week, the price has changed by -10.05%, over one month by -13.67%, over three months by -2.43% and over the past year by +92.24%.
Probably not. Based on ValueRay Fundamental Analyses, Procept Biorobotics (NASDAQ:PRCT) is currently (December 2024) not a good stock to buy. It has a ValueRay Fundamental Rating of -29.11 and therefor a somewhat negative outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of PRCT as of December 2024 is 89.28. This means that PRCT is currently overvalued and has a potential downside of 9.99%.
Procept Biorobotics has received a consensus analysts rating of 4.40. Therefor, it is recommend to buy PRCT.
- Strong Buy: 6
- Buy: 2
- Hold: 2
- Sell: 0
- Strong Sell: 0
According to ValueRays Forecast Model, PRCT Procept Biorobotics will be worth about 101 in December 2025. The stock is currently trading at 81.17. This means that the stock has a potential upside of +24.44%.
Issuer | Forecast | Upside |
---|---|---|
Wallstreet Target Price | 102.8 | 26.6% |
Analysts Target Price | 46.4 | -42.9% |
ValueRay Target Price | 101 | 24.4% |